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Adaptive immune response is part of the dynamic changes that
accompany motoneuron loss in amyotrophic lateral sclerosis (ALS).
CD4+ T cells that regulate a protective immunity during the neu-
rodegenerative process have received the most attention. CD8+
T cells are also observed in the spinal cord of patients and ALS mice
although their contribution to the disease still remains elusive. Here,
we found that activated CD8+ T lymphocytes infiltrate the central
nervous system (CNS) of a mouse model of ALS at the symptomatic
stage. Selective ablation of CD8+ T cells in mice expressing the ALS-
associated superoxide dismutase-1 (SOD1)G93A mutant decreased spi-
nal motoneuron loss. Using motoneuron-CD8+ T cell coculture sys-
tems, we found that mutant SOD1-expressing CD8+ T lymphocytes
selectively kill motoneurons. This cytotoxicity activity requires the
recognition of the peptide-MHC-I complex (where MHC-I represents
major histocompatibility complex class I). Measurement of interac-
tion strength by atomic force microscopy-based single-cell force spec-
troscopy demonstrated a specific MHC-I-dependent interaction
between motoneuron and SOD1G93A CD8+ T cells. Activated mutant
SOD1 CD8+ T cells produce interferon-γ, which elicits the expression
of the MHC-I complex in motoneurons and exerts their cytotoxic
function through Fas and granzyme pathways. In addition, analysis
of the clonal diversity of CD8+ T cells in the periphery and CNS of
ALS mice identified an antigen-restricted repertoire of their T cell
receptor in the CNS. Our results suggest that self-directed immune
response takes place during the course of the disease, contributing
to the selective elimination of a subset of motoneurons in ALS.
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Amyotrophic lateral sclerosis (ALS) is an incurable neuro-degenerative disease that primarily affects upper and lower
motoneurons. ALS has a complex multifactorial etiology as
reflected by the large predominance of sporadic forms of the
disease. Dominantly inherited mutations in the gene encoding su-
peroxide dismutase-1 (SOD1) are among the most common genetic
causes of hereditary ALS (1). Mice that express ALS-linked SOD1
mutations progressively develop a severe motoneuron disease that
presents the main traits of human pathology. Those ALS mouse
models have provided valuable clues to the cellular pathogenesis of
the disease. Whereas the neurodegenerative process selectively af-
fects motoneurons, non–cell-autonomous determinants that impli-
cate glial cells also contribute to the pathogenic process (2). The
neuroinflammatory environment resulting from functionally aber-
rant glial cells is additionally accompanied by the infiltration of
blood-derived immune cells (3).
Infiltration of CD4+ and CD8+ T lymphocytes has been
documented in the brain and spinal cord of ALS patients (4–6).
In transgenic mice expressing mutant SOD1G93A, the number of
CD4+ and CD8+ T cells infiltrating the spinal cord increases as
the disease progresses (7, 8). CD4+ T lymphocytes have gained a
certain interest due to their neuroprotective function in ALS.
This was evidenced by the reduced number and suppressive
abilities of T regulatory (Treg) lymphocytes, which are negatively
correlated with the progression rate of the disease in ALS pa-
tients (9, 10), and by genetic ablation of CD4 or adoptive transfer
of Treg on ALS pathogenesis in mice (7, 11, 12).
To typically mount an immune response, the T cell receptor
(TCR) of CD8+ T cells interacts with antigens presented by
heterodimeric MHC class I (MHC-I) molecules (13). MHC-I is
expressed by motoneurons both under physiological conditions
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and during the asymptomatic disease stage, whereas the percentage
of surviving motoneurons expressing MHC-I was found to be re-
duced in postmortem spinal cord samples of ALS patients as well as
in the spinal cord of end-stage mutant SOD1 mice (14). The light
chain of MHC-I β-2 microglobulin (β2m) is predominantly ex-
pressed by motoneurons, and expression increases during the dis-
ease progression (15). However, the contribution of a CD8+
cytotoxic T cell response to ALS pathogenesis still remains elusive.
Here, we observed that activated CD8+ T cells infiltrate the central
nervous system (CNS) of symptomatic ALS mice. SOD1G93A mice
depleted in CD8+ T cells exhibited an increased number of surviving
motoneurons. We found that purified SOD1G93A-expressing CD8+
T cells selectively trigger the death of primary motoneurons in a
MHC-I-dependent manner through granzyme and Fas death
pathways. Atomic force microscopy- (AFM-) based single-cell
force spectroscopy (AFM-SCFS) showed increased contact force
between ALS cytotoxic CD8+ T cells and motoneurons which
implicate MHC-I recognition. Finally, spectratyping analysis of the
TCR repertoire showed a restricted usage of the TCR β-chain
variable region (TRBV) by CD8+ T cells infiltrating the CNS
confirming an antigen-specific CD8+ T cell response in ALS mice.
Results
Activated CD8+ T Cells Infiltrate the CNS of ALS Mice During the
Symptomatic Stage. We first sought to determine the differentiation
profile of CD8+ T cells infiltrating the CNS of SOD1G93A -expressing
mice. We used a sequential gating strategy to accurately define
CD8+ T cells among the CD45+Thy1.2+CD49b−CD3+ T lym-
phocyte lineages in the CNS of ALS mice by flow cytometry (SI
Appendix, Fig. S1A). We first confirmed a significant accumulation
of CD8+ T cells in the CNS of SOD1G93A mice at the symptomatic
stage (150 d). Such an increase was not observed in the blood of
age-matched SOD1 mutant mice (SI Appendix, Fig. S1 B and C).
In situ hybridization using a Cd8a probe revealed a widespread
distribution of CD8+ T cells in the gray matter of the SOD1G93A
spinal cord (SI Appendix, Fig. S2). We next determined the dif-
ferentiation profile of infiltrating SOD1G93A CD8+ T cells by using
CD44 and CD62L markers whose levels distinguish between naive
(CD44−CD62L+) and effector/effector memory (CD44+CD62L−)
T cells. The frequency of CD44+CD62L− antigen-experienced
T cells in the CNS of SOD1G93A mice increased with the disease
progression (Fig. 1A). The majority of CD8+ T cells infiltrating the
CNS being mainly effector/effector memory T cells (Fig. 1B).
Markers of CD8+ T cell activation including killer cell lectinlike
receptor subfamily G member 1 (KLRG1) and CD25 were found
to be expressed by CD8+ T cells that accumulate in the CNS of
ALS mice (Fig. 1 C and D).
Depletion of Cytotoxic CD8+ T Cells in SOD1 Mutant Mice Increases
the Survival of Spinal Motoneurons. We next asked whether CD8+
T cells contribute to ALS pathogenesis. We bred SOD1G93A with
Cd8a-deficient mice. Cd8a−/− mice are viable and fertile but fail
to generate functional cytotoxic CD8+ T cells (16). We first en-
sured by flow cytometry analysis that the CD8+ T cell population
was lost without the CD4+ T cell population being affected in the
SOD1G93A;Cd8a−/− double mutant mice (SI Appendix, Fig. S3 A
and B). We did not observe any effect at disease onset, motor
performance, and life expectancy (SI Appendix, Fig. S4 A–D).
However, we found that the loss of CD8+ T cell function sig-
nificantly increased the number of surviving motoneurons in
SOD1G93A mice (Fig. 2). To further confirm this observation, we
repeatedly administrated a monoclonal anti-CD8 antibody to
selectively deplete CD8+ T cells in mice (17). Treatment led to a
marked and long-lasting reduction of blood-circulating CD8+
T cells without altering CD4+ T cells, CD19+ B cells, or CD11b+
macrophage populations (SI Appendix, Fig. S5 A–D). However,
only 40% of CD8+ T cells were depleted in the CNS compared
%
 o
f K
LR
G
1+
a
m
o
n
g 
CD
8+
 
T 
ce
lls
C
0
5
10
15
Peripheral CNS
* *
*
B
%
 o
f C
D4
4+
CD
62
L-
a
m
o
n
g 
CD
8+
 
T 
ce
lls
Peripheral CNS
0
20
40
60
80
100
90 120 150
age (days)
*********
%
 o
f C
D2
5+
a
m
o
n
g 
CD
8+
 
T 
ce
lls
D
***
Peripheral CNS
0
5
10
15
%
 o
f C
D8
+
CD
44
+
CD
62
L-
a
m
o
n
g 
re
co
ve
re
d 
ce
lls
A
0
0.2
0.4
0.6
0.8
1.0
1.2
**
90 120 150
age (days)
90 120 150
age (days)
90 120 150
age (days)
Fig. 1. Infiltration of activated CD8+ T cells in the CNS of SOD1G93A-
expressing mice. (A) Analysis of CD44 and CD62L expression on CD8+ T cells
isolated from the CNS of SOD1G93A mice at 90, 120, and 150 d of age (among
viable, single event cells, SI Appendix, Fig. S1A). (B) Flow cytometry analysis
indicating that the CD8+ T cells infiltrating the CNS are mainly CD44+CD62L−
compared with circulating CD8+ T cells (peripheral). (C and D) Percentage of
infiltrating CD8+ cells with expression of the KLRG1 (C) and CD25 (D) acti-
vation marker at indicated ages in the CNS and blood of SOD1G93A mice.
Histograms show mean values ± scanning electron microscopy (SEM), n = 3
for each time point, *P < 0.05, **P < 0.01, ***P < 0.001, analysis of variance
(ANOVA) with Tukey–Kramer’s post hoc test (A) or multiple t test (B–D).
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Fig. 2. Genetic depletion of CD8+ T lymphocytes increased the number of
surviving motoneurons in ALS mice. (A) Representative images of lumbar
spinal cord sections of 135-d-old mice of indicated genotype immunolabeled
with choline acetyltransferase (ChAT) to visualize motoneurons. (Scale bar,
50 μm.) (B) Quantification of the number of ChAT+ motoneurons in 45 sec-
tions of the lumbar spinal cord of Cd8a+/+, Cd8a−/−, SOD1G93A;Cd8a+/+ and
SOD1G93A;Cd8a−/− mice (n = 3). Values are means ± SEM; ***P < 0.001; n.s,
nonsignificant, ANOVA with Tukey–Kramer’s post hoc test.
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with 70% in the blood of SOD1G93A mice (SI Appendix, Fig. S5E).
Although CD8 depletion did not ameliorate motor decline or
extend the life span of SOD1G93Amice (SI Appendix, Fig. S6 A–C),
a significant increased survival of motoneurons was observed (SI
Appendix, Fig. S6D). Of note, the lower protective effect of CD8
depletion observed here might be explained by the partial de-
pletion of CD8+ T cell in the CNS and the preferential action of
the anti-CD8 antibody on the naive CD8+ T cell population (18).
SOD1G93A-Expressing CD8+ T Cells Selectively Kill Primary Motoneurons.
We cocultured mouse primary motoneurons and purified CD8+
T cells to investigate whether CD8+ T cells could directly mediate
cytotoxicity toward motoneurons (SI Appendix, Fig. S7A). The
presence of wild-type CD8+ T cells did not cause any loss of Hb9::
GFP motoneurons that express GFP under the control of the
motoneuron-selective Hb9 promoter to facilitate motoneuron
identification (Fig. 3A) (19). When CD8+ T cells were isolated
from the LNs of 150-d-old SOD1G93A mice, the percentage of
surviving motoneurons was not significantly altered after 24 h of
coculture but was significantly reduced by ∼40% after 48 h and
was unchanged after 72 or 96 h (Fig. 3A). CD8+ T cells isolated
from the LNs of SOD1 mutant mice have similar cytotoxicity to-
ward motoneurons to that of CD8+ T cells isolated from the CNS
(Fig. 3B). This neurotoxicity was only observed with CD8+ T cells
isolated from symptomatic mice (130 and 150 d of age) but not
from those isolated from asymptomatic 30-d-old SOD1G93A mice
(Fig. 3C). When motoneurons were cultured for 7 d prior addition
of SOD1G93A CD8+ T cells, we did not observe any effect on mo-
toneuron survival (Fig. 3D). We then asked whether the expression
of mutated SOD1 in motoneurons would render motoneurons more
susceptible to SOD1G93A CD8+ T lymphocyte cytotoxicity. The
survival of motoneurons expressing the SOD1G93A mutant was
identical to that of wild-type motoneurons in the presence of mutant
CD8+ T cells (Fig. 3E). The survival of SOD1G93A motoneurons
was not modified by the presence of wild-type CD8+ T cells (SI
Appendix, Fig. S7B). To determine whether mutant CD8+ T cell-
induced death was specific to motoneurons, the survival of hip-
pocampal, striatal, and cortical neurons was evaluated after 72 h
of coculture. The survival of other neuronal types was not affected
by the presence of lymphocytes isolated from wild-type mice or
mice expressing mutated SOD1 (SI Appendix, Fig. S7 C–E).
ALS CD8+ T Cells Recognize and Induce the Death of Motoneurons in a
MCH-I-Dependent Manner. We evaluated whether CD8+ T cells
expressing mutated SOD1 required cell-cell contact to trigger the
death of motoneurons. We used a coculture system with a transwell
insert and showed that SOD1 mutant cytotoxic CD8+ T lympho-
cytes require cell contact to trigger the death of motoneurons (Fig.
4A). To determine the requirement of antigen-MHCI-I recognition
by CD8+ T cells, we used a function-blocking anti-MHC-I H2-Db
antibody and observed that motoneurons were saved from CD8+
T cell cytotoxicity (Fig. 4B). To accurately quantify the strength of
CD8+ T lymphocyte-motoneuron interaction, we used AFM-SCFS
(SI Appendix, Fig. S8 A–D). Beginning with a dwelling time of 1 s,
the mean adhesion force between motoneurons and SOD1G93A
CD8+ T cells was higher than that obtained with wild-type lym-
phocytes (Fig. 4 C and D). By increasing the dwelling time to 5 s,
the magnitude of the binding strength of mutant CD8+ T cells with
motoneurons was increased, whereas the adhesion force between
wild-type CD8+ T cells and motoneurons remains stable, suggest-
ing nonspecific interaction (SI Appendix, Fig. S8 E and F). Blocking
TCR/MHC-I interaction, the anti-MHC-I antibody significantly
decreased adhesion force (Fig. 4E and SI Appendix, Fig. S8G).
ALS Mutant Cytotoxic T Cell-Mediated Death of Motoneurons Involves
Granzyme and Fas. CD8+ cytotoxic T cells eliminate target cells by
two major pathways: the perforin-mediated delivery of granzyme
serine proteases in the cytoplasm of target cells, resulting in effector
caspase activation, and the commitment of the Fas death pathway
(20). We first used the granzyme B inhibitor z-AAD-cmk at the
maximum concentration that motoneurons can tolerate and found
that it partly rescued motoneurons from cytotoxicity mediated by
SOD1G93A CD8+ T cells (Fig. 5A). When we then blocked Fas-FasL
interaction by Fas-Fc, the motoneurons were partly saved from
mutant CD8+ T cell-induced death (Fig. 5B). Granzyme B as
well as Fas converge both at the mitochondrial caspase-9 path-
way (21, 22). Consistently, treatment with the caspase-9 inhibitor
Ac-LEHD-cmk completely rescued the motoneurons from death in-
duced by SOD1G93A CD8+ T cells (Fig. 5C).
Fig. 3. Mutant SOD1-expressing CD8+ T cells selectively trigger the death of
motoneurons in vitro. (A) Motoneurons were isolated from Hb9::GFP (where
GFP represents green fluorescent protein) mice and cocultured for 24, 48, 72,
and 96 h with CD8+ T cells immunopurified from the lymph nodes (LNs) of wild-
type or SOD1G93A mice. Motoneuron survival was determined by direct count-
ing of GFP+ motoneurons and expressed relative to survival in the absence of
any T cells at 24 h. (B) CD8+ T cells were isolated either from the LNs or from the
CNS of SOD1 mutant mice and cocultured with wild-type motoneurons. (C) CD8+
T cells were isolated from the LNs of SOD1G93A mice at the indicated age and
cocultured with wild-type motoneurons. (D) CD8+ T cells were isolated from
SOD1G93Amice at 150 d of age and added to motoneurons at the time of seeding
(0) or 7 d later. (B–D) Survival was determined 72 h later and expressed relative
to the survival in the absence of T cells. (E) Motoneurons were isolated from
either wild-type or SOD1G93A mice and cocultured with SOD1 mutant CD8+
T cells. Motoneuron survival was determined after 72 h and expressed relative to
wild-type motoneurons cultured in the absence of T cells. The results shown are
the mean values ± standard deviation (SD) of, at least, three independent ex-
periments performed in triplicate. (B andD) Unpaired two-tailed t test, (A, C, and
E) ANOVA with Tukey–Kramer’s post hoc test. *P < 0.05; **P < 0.01; ***P <
0.001; n.s, nonsignificant.
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Activation of CD8+ T cells leads to interferon-γ (IFNγ) pro-
duction, which can contribute to cell killing through the up-
regulation of MHC-I in target cells (23). Intracellular staining
followed by flow cytometry showed that IFNγ is expressed at
higher levels in ALS mutant CD8+ T cells that are recruited to
the CNS compared with wild-type T cells in the blood and those
who patrol the CNS under physiological conditions (SI Appendix,
Fig. S9A) (24). Levels of IFNγ in the spinal cord of SOD1G93A
mice significantly increase with disease progression (19). We
asked whether increased levels of IFNγ might be associated with
increased MHC-I and β2m levels in the spinal cord. We observed
a significant increase in H2-Db and β2m transcript levels in the
spinal cord of SOD1G93A mice at 150 d of age compared with
age-matched wild-type and 90-d-old SOD1 mutant mice (SI
Appendix, Fig. S9 B and C). Motoneurons exposed to a sublethal
dose of recombinant IFNγ (19) significantly increased the
somatic expression of MHC-I (SI Appendix, Fig. S9 D and E) and
β2m that is required for transport and stabilization of MHC-I at the
cell surface (SI Appendix, Fig. S9 F and G). The addition of a
neutralizing anti-IFNγ antibody to the culture medium saved mo-
toneurons from death induced by SOD1G93A CD8+ T lymphocytes
(SI Appendix, Fig. S9H). Of note, wild-type motoneurons exposed to
IFNγ do not become susceptible to wild-type CD8+ T cells (SI
Appendix, Fig. S9I). We previously demonstrated that IFNγ triggers
the death of motoneurons through the activation of the lymphotoxin
β receptor (LT-βR) by tumor necrosis factor superfamily mem-
ber 14 (19). We observed that the decoy receptor LT-βR-Fc did
not rescue motoneurons from SOD1G93A CD8+ T cell-induced cy-
totoxicity (SI Appendix, Fig. S9J). These results show that acti-
vated IFNγ-producing SOD1G93A CD8+ T cells induce the death of
motoneurons through Fas and granzyme pathways, whereas IFNγ up-
regulates the expression of the MHC-I/β2m complex in motoneurons.
ALS CD8+ T Cells That Infiltrate the CNS Show a Restricted TCR
Repertoire. To confirm that autoreactive CD8+ T cells are se-
lectively recruited to the CNS of ALS mice, we analyzed the
TCR Vβ repertoire of infiltrated and peripheral CD8+ T cells by
spectratyping of the complementary determining region 3
(CDR3) of TRBV genes (25). We first determined the TRBV
CDR3 length distribution (CDR3-LD) of peripheral CD8+
T cells isolated from wild-type and SOD1G93A mice. The spec-
tratyping of 18 TRBV showed a normal distribution of CDR3
lengths in TRBV families between wild-type and ALS mice (SI
Appendix, Fig. S10 A and B). Interestingly, when we compared
the CDR3-LD from paired samples of peripheral and infiltrated
CD8+ T cells in SOD1 mutant mice, we observed a shift from
polyclonal to oligoclonal and monoclonal TRBV gene usage in
the CNS (Fig. 6A). To quantify the similarity of the TRBV
repertoire between peripheral and infiltrated CD8+ T cells, two
metrics were used, linear correlation and distance score (25).
We demonstrated that the TRBV repertoire of infiltrated CNS
CD8+ T cells differ from those of peripheral CD8+ T cells
A
C
D
E
B
Fig. 4. Mutant cytotoxic CD8+ T cells mediate the death of motoneurons in a
cell contact-, MHCI-dependent manner. (A) Wild-type and SOD1G93A CD8+
T cells were seeded with motoneurons for direct coculture (cell contact) or seeded
into the upper transwell chamber (no cell contact). (B) Function-blocking anti-
MHC-I antibody (1 μg/mL) was added to motoneurons cocultured with mutant
SOD1 CD8+ T cells. Motoneuron survival was determined after 72 h of coculture
and expressed relative to the absence of T cells (none). (C and D) Adhesion force
histograms obtained by recording force curves of wild-type (C) or SOD1G93A (D)
CD8+ T cells with wild-type motoneurons with a dwelling time of 1 s. (C) The
results represent seven cell pairs from two different cell cultures. (D) The results
represent 14 cell pairs from four different cell cultures. (E) Mean adhesion force
between wild-type or SOD1G93A CD8+ T cells and wild-type motoneurons in the
presence of an anti-MHC-I antibody with a dwelling time of 1 s. The values are
Gaussian fit means ± SD, ANOVAwith repeated measures, Newman–Keuls’s post
hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, n.s, nonsignificant.
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Fig. 5. SOD1G93A-expressing CD8+ T lymphocytes kill motoneurons through
both granzyme and Fas pathway. (A) The z-AAD-CMK granzyme B inhibitor
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Motoneuron-cytotoxic CD8+ lymphocyte cocultures were challenged with the
Fas-Fc chimera (1 μg/mL). (C) The selective inhibitor of the central executioner
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motoneurons cocultured or not with ALS mutant CD8+ T cells. In A–C, the
percentage of surviving GFP+ motoneurons was determined 72 h later and
expressed relative to the nontreated condition without the presence of CD8+
T cells. The values are means ± SD of, at least, three independent experiments
performed in triplicate, ANOVA with Tukey—Kramer’s post hoc test. *P < 0.05,
***P < 0.001.
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(SI Appendix, Fig. S11 A and B). We then analyzed the CDR3
length of the 18 TRBV individually to determine the relative use
of each in the CNS of SOD1G93Amice and observed a specific selection
of mTRBV15 (Fig. 6B and SI Appendix, Fig. S12). Consistently, a
targeted analysis of mTRBV15 CDR3-LD showed that CNS-
infiltrating mTRBV15 CD8+ T cells are also selectively de-
tected in the LNs (SI Appendix, Fig. S13).
Discussion
CD8+ T cell-mediated cytotoxic immune response plays a de-
terminant role in the elimination of virally infected or tumor cells.
Here, we provide evidence that SOD1G93A CD8+ effector T cells
recognize the self-peptide-MHC-I complex on motoneurons, in-
dependent of the expression of human SOD1G93A by motoneurons
that could have generated antigenic peptides. This might imply that
motoneuron-derived antigens have to be internalized by pro-
fessional antigen-presenting cells (APC) in the secondary lymphoid
organs and presented in the context of MHC-I, a process termed
cross presentation. Consistently, we found a mTRBV15 restricted
clonal diversity within the LNs and CNS of SOD1G93A mice. It is
therefore possible that motoneuron-specific antigens released dur-
ing the degenerative process may be accessible in the periphery to
mount a motoneuron-targeted immune response. Peripheral cap-
ture of a self-antigen by cross-presenting APC and priming of naive
T cells in LNs will then also be determinant in defining the homing
phenotype of activated CD8+ T cells (26).
Our observations pose the puzzle of the contribution of the
MHC-I/β2m complex in ALS pathogenesis. Indeed, as previously
reported, the surviving motoneurons at the end stage of the
disease show reduced levels of MHC-I and viral-mediated
overexpression of MHC-I heavy chain variants in the spinal
cord extended the lifespan of SOD1G93A mice (14). The reduced
levels of MHC-I on the surviving motoneurons observed (14) do
not necessarily exclude MHC-I-dependent killing of some mo-
toneuron populations by infiltrating CD8+ T cells. Either the
proportion of motoneurons that are targeted by cytotoxic T cells
have already been eliminated, those remaining that might be
eliminated by a MHC-I-independent mechanism (14), or the low
MHC-I expression levels are yet effective to promote recognition
and cytotoxicity by CD8+ T cells. Two studies have explored the
contribution of β2m in ALS pathogenesis. The first observed that
the genetic deletion of β2m in SOD1G93A mice does not influence
the disease onset but significantly reduces the life span of mice
(15), whereas the second found that the deletion of β2m in
SOD1G93A mice accelerates the disease onset and prolongs the
survival of mice (27). Despite the contradictory character of these
two observations, it is important to stress that, with regard to our
concerns, cells from β2m−/− are not completely devoid of MHC-I
cell surface expression and that cytotoxic CD8+ T lymphocytes can
still be generated and are able to trigger the death of β2m−/− target
cells in a MHC-I-restricted manner (28, 29). We cannot exclude
that subnormal levels of MHC-I are present at the surface of
β2m−/− motoneurons in the spinal cord, thus recognized and
eliminated by peptide-specific cytotoxic CD8+ T cells. Moreover,
the functions of β2m are not exclusively limited to classical MHC-I
molecules as illustrated by the phenotypic defects observed in
β2m-deficient mice with immunoglobulin (Ig) and albumin hy-
percatabolism reduced IFNγ production or iron overload (30).
The role of MHC-I in neuronal differentiation, synapse for-
mation and function, and plasticity has been documented (31).
MHC-I is also involved in the stabilization of inhibitory synapses
on motoneurons and regeneration following nerve lesion (32).
Forced expression of MHC-I negatively regulates glutamatergic
and γ-aminobutyric acidergic synaptic transmission. The effect of
MHC-I on synaptic density is independent of bound β2m (33).
MHC-I can also bind to the paired Ig-like receptor B and restrict
synaptic plasticity as well as functional recovery following ischemic
damage (34). In addition, β2m can associate with CD1 family
members, Qa, the MHC-related-1 protein MR1, the neonatale Fc
receptor FcRn, and human hemochromatosis protein (30), whose
functions in the CNS remain elusive. The study of these additional
immune-independent mechanisms might be considered to gain
further insight into ALS pathogenic mechanisms.
Our paper raises questions concerning the functional charac-
teristics of motoneurons whose death is induced by CD8+ T cells
in vivo. Indeed, we observed a significant increase in the number
of spinal motoneurons following the depletion of CD8+ T cells in
ALS mice without any change in motor decline or life expec-
tancy. These findings suggest that nonfunctional motoneurons
might be eliminated by an orchestrated cell death program
triggered by CD8+ T lymphocytes for proper removal. Alterna-
tively, aberrant motoneuron electrical activity or those committed
to die by the dying-back process induce changes in gene expression
that might generate new autoantigens and killing by cytotoxic
CD8+ T cells. The latter have yet to be identified. We observed
that IFNγ can elicit MHC-I expression on mouse primary moto-
neurons as previously observed with rat primary motoneurons
(35). IFNγ can be produced by activated CD8+ T cells as well as
ALS astrocytes (19) to elicit and/or maintain sufficient MHC-I
expression levels on motoneurons allowing them to be recog-
nized by self-reactive cytotoxic CD8+ T cells. It is noteworthy that
somatic expression of MHC-I occurred in the presence of IFNγ
only in electrically silent neurons (36). Interestingly, the cytotox-
icity of mutant CD8+ lymphocytes is observed on electrically im-
mature motoneurons but not on those that after 7 d in vitro
become electrically mature as we showed previously (37, 38).
Cytotoxic CD8+ T cells could thus contribute to the elimination of
nonfunctional motoneurons during the disease.
Together, these results suggest that an autoimmune T cell
response contributes to ALS pathogenesis. The presence of au-
toantibodies in the cerebrospinal fluid (CSF) or serum of patients,
the cytotoxicity of the CSF from ALS patients toward neurons
in vitro signs of systemic immune activation in the serum, and the
CSF of ALS patients and the infiltration of T cells have suggested
that autoimmunity might contribute to ALS etiology and patho-
genesis (3, 39). Early clinical interventions targeting autoimmunity
through the administration of cyclophosphamide (40, 41); plas-
mapheresis combined with immunosuppression (42); or treatment
with azathioprine and prednisone (43) led to disappointing results
in patients. Despite all that, the state of our current knowledge
about the complexity of the immune response with respect to the
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Fig. 6. CD8+ T cells infiltrating the spinal cord of ALS mice show a restricted
T cell receptor repertoire. (A) Comparison of CDR3-LD (polyclonal, oligoclo-
nal, or monoclonal distribution) of TRBV families in CD8+ T cells isolated from
LNs (peripheral) and CNS (infiltrated) of 150-d-old SOD1G93A mice (n = 6). (B)
Distribution of the mTRBV15 CDR3 length across the CD8+ T cell infiltrating the
CNS shared among four mice (each color corresponding to one mouse).
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functional identity of lymphocyte subpopulations and the dy-
namics of this response during the course of the disease as well as
our present findings prompt us to critically reconsider these early
clinical data. The use of drugs with an unfocused spectrum of
action (cyclophosphamide and azathioprine inhibit DNA replica-
tion and cell proliferation, and prednisone is an antiinflammatory
and immunosuppressant synthetic glucocorticoid) does not afford
relevant insight into the selective contribution of autoimmunity in
ALS. Overall, this paper provides evidence of autoreactive CD8+
T cells that directly interact with and trigger the death of moto-
neurons. The inherent challenge is now to identify autoantigens
that are recognized by those cytotoxic T cells and to define per-
tinent combinatorial therapeutic approaches embracing the com-
plexity of the immune response in ALS.
Materials and Methods
Detailed information for animal experimentation, CD8+ T cell isolation,
fluorescence-activated cell sorting, in situ hybridization, primary neuron
cultures, neuron-CD8+ T cell cocultures, immunostaining, CD8+ T cell depletion,
atomic force microscopy-based single-cell force spectroscopy, the reverse
transcription quantitative polymerase chain reaction, TCR repertoire analysis,
and statistical analysis is provided in SI Appendix, Materials and Methods.
All animal experiments were approved by the national ethics committee
on animal experimentation, and were performed in compliance with the
European community and national directives for the care and use of laboratory
animals.
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